AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 82 min read$TENX

One manager just reported a 14% holding in Tenax Therapeutics (TENX)

ADAR1 Capital Management and its manager, Daniel Schneeberger, reported a 14% stake in Tenax Therapeutics (TENX), owning 5,257,389 shares as of July 28, 2026. They also hold warrants for additional shares, excluded due to a 4.99% ownership cap.

Original reporting
stocktitan.net
Published Sep 8, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TENX
Neutral
medium confidence
Mentioned
$TENX
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TENXNeutralLow
01

Why it matters

The filing adds transparency but does not announce new corporate actions.

02

Market read

Provides first public disclosure of a significant passive holder in TENX, modest relevance for traders.

03

What to watch

Potential future warrant exercises could increase effective ownership beyond 14%.

Relevance 5/10Novelty 6/10Timing: post-filing

Background

Schedule 13G filings are required for investors surpassing 5% ownership, providing transparency on large shareholders.

Company-level read

Ticker impact

$TENXNeutralMedium confidence
Context

Schedule 13G filing discloses ADAR1 Capital Management's 14% beneficial ownership of TENX shares as of July 28, 2026.

Expected impact

Modest upward pressure if market perceives increased institutional support.

Evidence & confidence

A 14% passive stake is sizable for a micro‑cap biotech, but no immediate corporate action is announced.

Market effects

Sector

May signal growing investor interest in biotech sector small‑caps.

Regional

Limited to U.S. biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

The stake could be a passive holding with no intent to influence, limiting price effect.

Key entities

  • investment manager
    ADAR1 Capital Management, LLC

    Manager of the disclosed 14% stake in TENX.

  • individual
    Daniel Schneeberger

    Sole manager of ADAR1 and control person filing.

Read at source← All news

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min
AUG 11
$TENXHighAI 9/10

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF

Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.

thepharmaletter.com2 min